Foresee Pharmaceuticals Co., Ltd.(“Foresee”) is a clinical-stage pharmaceutical company focusing on unmet medical needs. With its proprietary drug delivery platform technology as well as rational drug design technology, Foresee has several drug candidates under clinical development. In 2020, the most advanced product, FP-001 LMIS 50mg, is developed to treat prostate cancer. The other drug candidate under clinical investigation, FP-025, originally designed to treat asthma, has shown protective effects to lung cells and shed light on treating Covid-19 patients.
Foresee Pharmaceuticals Co., Ltd. has been listed on Taipei Exchange since June 2018.